Results 11 to 20 of about 447,491 (216)

Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine

Ca-A Cancer Journal for Clinicians, 2020
Soft‐tissue sarcomas (STS) are rare tumors that account for 1% of all adult malignancies, with over 100 different histologic subtypes occurring predominately in the trunk, extremity, and retroperitoneum. This low incidence is further complicated by their
Adriana C Gamboa, Alessandro Gronchi, Kenneth Cardona, Facs   +2 more
exaly   +2 more sources

The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study [PDF]

Cancer, 2016
Because the efficacy and safety of pazopanib in Japanese patients with soft tissue sarcoma (STS) had not been evaluated previously in a large‐scale cohort, the authors investigated the efficacy and safety of pazopanib in 156 Japanese patients with ...
Tomoki Nakamura, Akihiko Matsumine, Akira Kawai, Nobuhito Araki, Takahiro Goto, Tsukasa Yonemoto, Hideshi Sugiura, Yoshihiro Nishida, Hiroaki Hiraga, Kanya Honoki, Taketoshi Yasuda, Shogen Boku, Akihiro Sudo, Takafumi Ueda   +13 more
openalex   +2 more sources

Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives [PDF]

Advances in Therapy, 2016
Trabectedin (ET743, Yondelis®, manufactured by Baxter Oncology GmbH, Halle/Westfalen, Germany, for Janssen Products, LP, Horsham, PA), derived from the marine ascidian, Ecteinascidia turbinata, is a natural alkaloid with multiple complex mechanisms of ...
Erlinda M. Gordon, Kamalesh K. Sankhala, Neal Shiv Chawla, Sant P. Chawla   +3 more
openalex   +2 more sources

Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2022
Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues.
M. von Mehren, J. Kane, M. Agulnik, M. Bui, Janai R. Carr-Ascher, E. Choy, M. Connelly, Sarah Dry, K. Ganjoo, Ricardo J. Gonzalez, A. Holder, J. Homsi, V. Keedy, C. Kelly, Edward Kim, D. Liebner, M. McCarter, Sean V. McGarry, N. Mesko, C. Meyer, A. Pappo, A. Parkes, I. Petersen, S. Pollack, M. Poppe, R. Riedel, S. Schuetze, J. Shabason, J. Sicklick, M. Spraker, M. Zimel, Lisa E Hang, Hema M Sundar, Mary Anne Bergman   +33 more
semanticscholar   +1 more source

Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas: Standard of Care and Treatment Recommendations from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

Cancer Management and Research, 2022
This paper describes the standard of care for patients with non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) and the therapeutic recommendations developed by the European paediatric Soft tissue sarcoma Study Group (EpSSG).
A. Ferrari, B. Brennan, M. Casanova, N. Corradini, P. Berlanga, R. Schoot, Gema L Ramírez-Villar, A. Safwat, G. Guillén Burrieza, P. Dall'Igna, R. Alaggio, Lisa Lyngsie Hjalgrim, S. Gatz, D. Orbach, Max M. van Noesel   +14 more
semanticscholar   +1 more source

Avelumab use in Merkel cell carcinoma treatment

Nowotwory, 2022
Avelumab is a programmed death-ligand 1 (PD-L1) blocking human IgG1 lambda monoclonal antibody. It was the first immunotherapy to be approved for the treatment of MCC.
Monika Dudzisz-Śledź, Martyna Zwierzchowska, Elżbieta Bylina, Piotr Rutkowski, Anna M. Czarnecka   +4 more
doaj   +1 more source

Definitive Radiotherapy in the Management of Non-Resectable or Residual Retroperitoneal Sarcomas: Institutional Cohort Analysis and Systematic Review

Cancer Control, 2021
Background: There is currently no consensus on optimal management of patients with primary or recurrent non-resectable/residual retroperitoneal sarcomas (RPS). The objective of this study was to document the outcomes of patients with primary or recurrent
Aleksandra Sobiborowicz, Mateusz Jacek Spałek MD, PhD, Anna Małgorzata Czarnecka MD, PhD, MSc, Piotr Rutkowski MD, PhD   +3 more
doaj   +1 more source

Treatment of metastatic uveal melanoma

Nowotwory, 2022
Uveal melanoma is a rare malignancy with a poor prognosis. The risk of metastatic disease (mainly to the liver) exceeds 50% and is often observed many years after the primary treatment.
Mateusz M. Polaczek, Hanna Koseła-Paterczyk   +1 more
doaj   +1 more source

Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

Nature Communications, 2022
There are more than 70 distinct sarcomas, and this diversity complicates the development of precision-based therapeutics for these cancers. Prospective comprehensive genomic profiling could overcome this challenge by providing insight into sarcomas ...
M. Gounder, Narasimhan P. Agaram, S. Trabucco, V. Robinson, Richard A Ferraro, S. Millis, Anita Krishnan, Jessica K. Lee, S. Attia, W. Abida, A. Drilon, Ping Chi, Sandra P D' Angelo, M. Dickson, M. Keohan, C. Kelly, M. Agulnik, S. Chawla, E. Choy, R. Chugh, C. Meyer, P. Myer, Jessica L Moore, R. Okimoto, R. Pollock, V. Ravi, Arun S. Singh, N. Somaiah, A. Wagner, J. Healey, G. Frampton, J. Venstrom, J. Ross, M. Ladanyi, S. Singer, M. Brennan, G. Schwartz, A. Lazar, D. Thomas, R. Maki, W. Tap, Siraj M. Ali, D. Jin   +42 more
semanticscholar   +1 more source

Postępowanie diagnostyczno-terapeutyczne u chorych na czerniaki oka — zalecenia eksperckie Polskiego Towarzystwa Onkologicznego

Nowotwory, 2022
< p > < /p >
Piotr Rutkowski, Bożena Romanowska-Dixon, Anna Markiewicz, Krzysztof Zieniewicz, Katarzyna Kozak, Paweł Rogala, Tomasz Świtaj, Monika Dudzisz-Sledź   +7 more
doaj   +1 more source